Jeremy Graff, Ph.D., has devoted the last 30 years to researching the molecular mechanisms driving metastatic disease and to developing novel therapeutics for treating patients with metastatic cancers. Prior to joining HiberCell, Jeremy was president and chief scientific officer at Biothera Pharmaceuticals, Inc. where he led the Team advancing the clinical development of Imprime PGG. He was the Biothera executive responsible for orchestrating a deal for the acquisition of Imprime PGG and the entire Biothera clinical and research staff by HiberCell. In his 17-year tenure at Eli Lilly and Company, he led numerous small and large molecule efforts to the clinic and built and led Lilly’s Translational Oncology Effort, an initiative committed to deploying a deep scientific understanding of drug and disease to foster an enhanced likelihood of clinical and regulatory success.
Jeremy has been awarded numerous patents. He has published nearly 60 peer-reviewed research articles that collectively have garnered more than 18,000 research citations. He has served as a grant review panelist for the NIH/NIDDK, the American Cancer Society, Genome Quebec and the US Department of Defense. He serves on the editorial board for Cancer Research. He received his Ph.D. from the University of Kentucky and conducted his postdoctoral studies at Johns Hopkins University Medical School.